Antibodies that bind egfr and cmet

A method of treating a subject that has a tumor or a disease involving aberrant cells, the method comprising administering to an individual in need thereof a bispecific antibody that comprises a first variable domain that can bind an extracellular part of human epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of human MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET);

• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYNANTNYAQKLQG (SEQ ID NO:155), and a CDR3 comprising the sequence DRHWHWWLDA (SEQ ID NO:139), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence TYSMN (SEQ ID NO:
• 152), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:157), and a CDR3 comprising the sequence ETYFYDRGGYPFDP (SEQ ID NO:
• 31);
• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYNANTNYAQKLQG (SEQ ID NO:155), and a CDR3 comprising the sequence DRHWHWWLDAFDY (SEQ ID NO:37), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence TYSMN (SEQ ID NO:
• 152), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:157), and a CDR3 comprising the sequence ETYFYDRGGYPFDP (SEQ ID NO:
• 31);
• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYSGNTNYAQKLQG (SEQ ID NO:140), and a CDR3 comprising the sequence DRHWHWWLDA (SEQ ID NO:139), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence TYSMN (SEQ ID NO:
• 152), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:157), and a CDR3 comprising the sequence ETYFYDRGGYPFDP (SEQ ID NO:
• 31);
• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYSGNTNYAQKLQG (SEQ ID NO:140), and a CDR3 comprising the sequence DRHWHWWLDA (SEQ ID NO:139), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence SYSMN (SEQ ID NO:
• 28), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:
• 157), and a CDR3 sequence ETYYYDRGGYPFDP (SEQ ID NO:
• 30);
• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYSGNTNYAQKLQG (SEQ ID NO:140), and a CDR3 comprising the sequence DRHWHWWLDAFDY (SEQ ID NO:37), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence SYSMN (SEQ ID NO:
• 28), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:
• 157), and a CDR3 sequence ETYYYDRGGYPFDP (SEQ ID NO:
• 30);
• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYNANTNYAQKLQG (SEQ ID NO:155), and a CDR3 comprising the sequence DRHWHWWLDAFDY (SEQ ID NO:
• 37), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence SYSMN (SEQ ID NO:
• 28), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:
• 157), and a CDR3 sequence ETYYYDRGGYPFDP (SEQ ID NO:
• 30);
• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYNGNTNYAQKLQG (SEQ ID NO:113), and a CDR3 comprising the sequence DRHWHWWLDAFDY (SEQ ID NO:
• 37), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence TYSMN (SEQ ID NO:
• 152), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:157), and a CDR3 comprising the sequence ETYFYDRGGYPFDP (SEQ ID NO:
• 31);
• or
• wherein the first variable domain comprises a heavy chain variable region with a CDR1 sequence SYGIS (SEQ ID NO:
• 24), a CDR2 sequence WISAYNGNTNYAQKLQG (SEQ ID NO:113), and a CDR3 comprising the sequence DRHWHWWLDAFDY (SEQ ID NO:
• 37), and wherein the second variable domain comprises a heavy chain variable region with a CDR1 sequence SYSMN (SEQ ID NO:
• 28), a CDR2 sequence WINTYTGDPTYAQGFTG (SEQ ID NO:
• 157), and a CDR3 sequence ETYYYDRGGYPFDP (SEQ ID NO:
• 30);
• and
• wherein the first and second variable domains further comprise a common light chain variable domain comprising a CDR1 sequence QSISSY (SEQ ID NO:38), a CDR2 sequence AAS, and a CDR3 sequence QQSYSTP (SEQ ID NO:
• 39).